Report: Exploring Fundamental Drivers Behind SkyWest, Blueprint Medicines, HP, Hewlett Packard Enterprise, Cardinal Health, and The Medicines — New Horizons, Emerging Trends, and Upcoming Developments

NEW YORK, Nov. 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SkyWest, Inc. (NASDAQ:SKYW), Blueprint Medicines Corporation (NASDAQ:BPMC), HP Inc. (NYSE:HPQ), Hewlett Packard Enterprise Company (NYSE:HPE), Cardinal Health, Inc. (NYSE:CAH), and The Medicines Company (NASDAQ:MDCO), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

SKYW DOWNLOAD: http://Fundamental-Markets.com/register/?so=SKYW
BPMC DOWNLOAD: http://Fundamental-Markets.com/register/?so=BPMC
HPQ DOWNLOAD: http://Fundamental-Markets.com/register/?so=HPQ
HPE DOWNLOAD: http://Fundamental-Markets.com/register/?so=HPE
CAH DOWNLOAD: http://Fundamental-Markets.com/register/?so=CAH
MDCO DOWNLOAD: http://Fundamental-Markets.com/register/?so=MDCO

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine SkyWest, Inc. (NASDAQ:SKYW), Blueprint Medicines Corporation (NASDAQ:BPMC), HP Inc. (NYSE:HPQ), Hewlett Packard Enterprise Company (NYSE:HPE), Cardinal Health, Inc. (NYSE:CAH), and The Medicines Company (NASDAQ:MDCO) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 1st, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

SkyWest, Inc. (SKYW) REPORT OVERVIEW

SkyWest's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, SkyWest reported revenue of $805.52MM vs $791.51MM (up 1.77%) and analysts estimated basic earnings per share $1.46 vs $0.98 (up 48.98%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, SkyWest reported revenue of $3,204.27MM vs $3,121.21MM (up 2.66%) and analysts estimated basic earnings per share $8.28 vs -$3.14. Analysts expect earnings to be released on February 7th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.81. The estimated EPS forecast for the next fiscal year is $5.51 and is expected to report on February 7th, 2019.

To read the full SkyWest, Inc. (SKYW) report, download it here: http://Fundamental-Markets.com/register/?so=SKYW

-----------------------------------------

Blueprint Medicines Corporation (BPMC) REPORT OVERVIEW

Blueprint Medicines' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Blueprint Medicines reported revenue of $1.10MM vs $8.07MM (down 86.43%) and analysts estimated basic earnings per share -$1.66 vs -$0.96. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Blueprint Medicines reported revenue of $21.43MM vs $27.77MM (down 22.85%) and analysts estimated basic earnings per share -$3.92 vs -$2.64. Analysts expect earnings to be released on February 20th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$1.23. The estimated EPS forecast for the next fiscal year is -$7.55 and is expected to report on February 20th, 2019.

To read the full Blueprint Medicines Corporation (BPMC) report, download it here: http://Fundamental-Markets.com/register/?so=BPMC

-----------------------------------------

HP Inc. (HPQ) REPORT OVERVIEW

HP's Recent Financial Performance

For the three months ended July 31st, 2018 vs July 31st, 2017, HP reported revenue of $14,586.00MM vs $13,060.00MM (up 11.68%) and analysts estimated basic earnings per share $0.55 vs $0.41 (up 34.15%). For the twelve months ended October 31st, 2017 vs October 31st, 2016, HP reported revenue of $52,056.00MM vs $48,238.00MM (up 7.91%) and analysts estimated basic earnings per share $1.50 vs $1.44 (up 4.17%). Analysts expect earnings to be released on November 20th, 2018. The report will be for the fiscal period ending October 31st, 2018. Reported EPS for the same quarter last year was $0.44. The estimated EPS forecast for the next fiscal year is $2.18 and is expected to report on November 20th, 2018.

To read the full HP Inc. (HPQ) report, download it here: http://Fundamental-Markets.com/register/?so=HPQ

-----------------------------------------

Hewlett Packard Enterprise Company (HPE) REPORT OVERVIEW

Hewlett Packard Enterprise's Recent Financial Performance

For the three months ended July 31st, 2018 vs July 31st, 2017, Hewlett Packard Enterprise reported revenue of $7,764.00MM vs $7,501.00MM (up 3.51%) and basic earnings per share $0.30 vs $0.10 (up 200.00%). For the twelve months ended October 31st, 2017 vs October 31st, 2016, Hewlett Packard Enterprise reported revenue of $28,871.00MM vs $30,280.00MM (down 4.65%) and analysts estimated basic earnings per share $0.21 vs $1.84 (down 88.59%). Analysts expect earnings to be released on November 20th, 2018. The report will be for the fiscal period ending October 31st, 2018. The reported EPS for the same quarter last year was $0.29. The estimated EPS forecast for the next fiscal year is $1.58 and is expected to report on November 20th, 2018.

To read the full Hewlett Packard Enterprise Company (HPE) report, download it here: http://Fundamental-Markets.com/register/?so=HPE

-----------------------------------------

Cardinal Health, Inc. (CAH) REPORT OVERVIEW

Cardinal Health's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Cardinal Health reported revenue of $35,349.00MM vs $32,966.00MM (up 7.23%) and analysts estimated basic earnings per share -$3.70 vs $0.86. For the twelve months ended June 30th, 2018 vs June 30th, 2017, Cardinal Health reported revenue of $136,809.00MM vs $129,976.00MM (up 5.26%) and analysts estimated basic earnings per share $0.82 vs $4.06 (down 79.80%). Analysts expect earnings to be released on November 8th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $1.09. The estimated EPS forecast for the next fiscal year is $5.41 and is expected to report on August 5th, 2019.

To read the full Cardinal Health, Inc. (CAH) report, download it here: http://Fundamental-Markets.com/register/?so=CAH

-----------------------------------------

The Medicines Company (MDCO) REPORT OVERVIEW

The Medicines' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, The Medicines reported revenue of $1.67MM vs $10.86MM (down 84.65%) and analysts estimated basic earnings per share -$0.74 vs -$5.53. For the twelve months ended December 31st, 2017 vs December 31st, 2016, The Medicines reported revenue of $44.79MM vs $143.16MM (down 68.71%) and analysts estimated basic earnings per share -$9.79 vs -$1.71. Analysts expect earnings to be released on November 8th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.42. The estimated EPS forecast for the next fiscal year is -$1.15 and is expected to report on February 20th, 2019.

To read the full The Medicines Company (MDCO) report, download it here: http://Fundamental-Markets.com/register/?so=MDCO

-----------------------------------------

ABOUT Fundamental Markets

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: [email protected]

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.